These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36336279)

  • 1. Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity.
    Yaribeygi H; Maleki M; Butler AE; Jamialahmadi T; Sahebkar A
    Eur J Pharm Sci; 2023 Jan; 180():106322. PubMed ID: 36336279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of GLP-1 Mimetics on Epicardial Adiposity.
    Yaribeygi H; Maleki M; Nasimi F; Jamialahmadi T; Stanford FC; Sahebkar A
    Curr Med Chem; 2023; 30(37):4256-4265. PubMed ID: 36642880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors and autophagy in diabetes.
    Yaribeygi H; Maleki M; Atkin SL; Jamialahmadi T; Sahebkar A
    Cell Biochem Funct; 2023 Jun; 41(4):392-398. PubMed ID: 37036046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes.
    Niknejad A; Hosseini Y; Shamsnia HS; Kashani AS; Rostamian F; Momtaz S; Abdolghaffari AH
    Cell Biochem Biophys; 2023 Dec; 81(4):599-613. PubMed ID: 37658280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes.
    Burgeiro A; Fuhrmann A; Cherian S; Espinoza D; Jarak I; Carvalho RA; Loureiro M; Patrício M; Antunes M; Carvalho E
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E550-64. PubMed ID: 26814014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors in COVID-19.
    Yaribeygi H; Maleki M; Atkin SL; Kesharwani P; Jamialahmadi T; Sahebkar A
    IUBMB Life; 2023 Aug; 75(8):648-658. PubMed ID: 36971045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into cellular links between sodium-glucose cotransporter-2 inhibitors and ketogenesis.
    Yaribeygi H; Maleki M; Butler AE; Jamialahmadi T; Sahebkar A
    J Cell Biochem; 2022 Dec; 123(12):1879-1890. PubMed ID: 36153819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epicardial Adipose Tissue and Heart Failure, Friend or Foe?
    Cho DH; Park SM
    Diabetes Metab J; 2024 May; 48(3):373-384. PubMed ID: 38310880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.
    Iacobellis G; Baroni MG
    J Endocrinol Invest; 2022 Mar; 45(3):489-495. PubMed ID: 34643917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.
    Iacobellis G; Basilico S; Malavazos AE
    Handb Exp Pharmacol; 2022; 274():93-108. PubMed ID: 35156138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review.
    Shakour N; Karami S; Iranshahi M; Butler AE; Sahebkar A
    Diabetes Metab Syndr; 2024 Jan; 18(1):102934. PubMed ID: 38154403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
    Packer M
    J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Nat Rev Endocrinol; 2020 Oct; 16(10):556-577. PubMed ID: 32855502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Euh W; Lim S; Kim JW
    Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibitors and hematopoiesis.
    Yaribeygi H; Maleki M; Nasimi F; Butler AE; Jamialahmadi T; Sahebkar A
    J Cell Physiol; 2022 Oct; 237(10):3778-3787. PubMed ID: 35951776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.
    Zelniker TA; Braunwald E
    J Am Coll Cardiol; 2018 Oct; 72(15):1845-1855. PubMed ID: 30075873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.